6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

L	NNP	l	l	l	N	O
ong	MD	ong	ong	ong	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta	NN	beta	beta	beta	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
adrenergic	NN	adrenergic	adrenergic	adrenerg	N	O
agonists	NNS	agonists	agonist	agonist	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
A	NNP	a	a	a	N	O
RCAPTA	NNP	rcapta	rcapta	rcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
,	,	,	,	,	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	B-AdverseReaction
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
[	NNP	[	[	[	N	O
See	NNP	see	see	see	N	O
B	NNP	b	b	b	N	O
oxed	VBD	oxed	oxed	oxe	N	O
Warning	NNP	warning	warning	warn	N	O
and	CC	and	and	and	N	O
W	NNP	w	w	w	N	O
arning	NN	arning	arning	arn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
and	CC	and	and	and	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
cough	JJ	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Novartis	NNP	novartis	novartis	novarti	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
Corporation	NNP	corporation	corporation	corpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
669	CD	669	669	669	N	O
-	:	-	-	-	N	O
6682	CD	6682	6682	6682	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Chronic	NNP	chronic	chronic	chronic	N	B-AdverseReaction
Obstructive	NNP	obstructive	obstructive	obstruct	N	I-AdverseReaction
Pulmonary	NNP	pulmonary	pulmonary	pulmonari	N	I-AdverseReaction
Disease	NNP	disease	disease	diseas	N	I-AdverseReaction

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
safety	NN	safety	safety	safeti	N	O
database	NN	database	database	databas	N	O
reflects	VBZ	reflects	reflects	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
2516	CD	2516	2516	2516	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
75	CD	75	75	75	N	O
mcg	NN	mcg	mcg	mcg	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
12	CD	12	12	12	N	O
weeks	NNS	weeks	week	week	N	O
in	IN	in	in	in	N	O
six	CD	six	six	six	N	O
confirmatory	NN	confirmatory	confirmatory	confirmatori	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Section	NNP	section	section	section	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
449	CD	449	449	449	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
75	CD	75	75	75	N	O
mcg	NN	mcg	mcg	mcg	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
144	CD	144	144	144	N	O
,	,	,	,	,	N	O
583	CD	583	583	583	N	O
and	CC	and	and	and	N	O
425	CD	425	425	425	N	O
COPD	NNP	copd	copd	copd	Y	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
150	CD	150	150	150	N	O
,	,	,	,	,	N	O
300	CD	300	300	300	N	O
or	CC	or	or	or	N	O
600	CD	600	600	600	N	O
mcg	NN	mcg	mcg	mcg	N	O
for	IN	for	for	for	N	O
one	CD	one	one	one	N	O
year	NN	year	year	year	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
bronchodilator	NN	bronchodilator	bronchodilator	bronchodil	N	O
forced	VBD	forced	forced	forc	N	O
expiratory	JJ	expiratory	expiratory	expiratori	N	O
volume	NN	volume	volume	volum	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
second	NN	second	second	second	N	O
(	(	(	(	(	N	O
FEV1	NNP	fev1	fev1	fev1	N	O
)	)	)	)	)	N	O
percent	NN	percent	percent	percent	N	O
predicted	VBD	predicted	predicted	predict	N	O
of	IN	of	of	of	N	O
54%	CD	54%	54%	54%	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
64	CD	64	64	64	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
47%	CD	47%	47%	47%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
aged	VBN	aged	aged	age	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
older	JJR	older	older	older	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
(	(	(	(	(	N	O
88%	CD	88%	88%	88%	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
six	CD	six	six	six	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
48%	CD	48%	48%	48%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
any	DT	any	any	ani	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
reported	VBD	reported	reported	report	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
43%	CD	43%	43%	43%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
5%	CD	5%	5%	5%	N	O
for	IN	for	for	for	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
5%	CD	5%	5%	5%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
lead	VBP	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
were	VBD	were	were	were	N	O
COPD	NNP	copd	copd	copd	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
COPD	NNP	copd	copd	copd	Y	B-AdverseReaction
exacerbation	NN	exacerbation	exacerbation	exacerb	N	I-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
angina	JJ	angina	angina	angina	N	B-AdverseReaction
pectoris	NN	pectoris	pectoris	pectori	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
similar	JJ	similar	similar	similar	N	O
rates	NNS	rates	rate	rate	N	O
across	IN	across	across	across	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
displays	NNS	displays	display	display	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
during	IN	during	during	dure	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
month	NN	month	month	month	N	O
exposure	NN	exposure	exposure	exposur	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
75	CD	75	75	75	N	O
mcg	NN	mcg	mcg	mcg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
listed	VBN	listed	listed	list	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
(	(	(	(	(	N	O
version	NN	version	version	version	N	O
13.0	CD	13.0	13.0	13.0	N	O
)	)	)	)	)	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
and	CC	and	and	and	N	O
sorted	VBN	sorted	sorted	sort	N	O
in	IN	in	in	in	N	O
descending	VBG	descending	descending	descend	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
frequency	NN	frequency	frequency	frequenc	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Number	NNP	number	number	number	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
COPD	NNP	copd	copd	copd	Y	O
patients	NNS	patients	patient	patient	N	O
exposed	VBD	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
75	CD	75	75	75	N	O
mcg	NN	mcg	mcg	mcg	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
in	IN	in	in	in	N	O
multiple	JJ	multiple	multiple	multipl	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
controlled	VBD	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O

Indacaterol	NNP	indacaterol	indacaterol	indacaterol	N	O
75	CD	75	75	75	N	O
mcg	NN	mcg	mcg	mcg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
Placebo	NNP	placebo	placebo	placebo	N	O

n	RB	n	n	n	N	O
449	CD	449	449	449	N	O
n	NNS	n	n	n	N	O
445	CD	445	445	445	N	O

n	RB	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

-	:	-	-	-	N	O
Cough	NN	cough	cough	cough	Y	B-AdverseReaction
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
6.5	CD	6.5	6.5	6.5	N	O
)	)	)	)	)	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
4.5	CD	4.5	4.5	4.5	N	O
)	)	)	)	)	N	O

-	:	-	-	-	N	O
Oropharyngeal	NN	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.7	CD	0.7	0.7	0.7	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

-	:	-	-	-	N	O
Nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
2.7	CD	2.7	2.7	2.7	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

-	:	-	-	-	N	O
Headache	NN	headache	headache	headach	Y	B-AdverseReaction
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
2.5	CD	2.5	2.5	2.5	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

-	:	-	-	-	N	O
Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.9	CD	0.9	0.9	0.9	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
for	IN	for	for	for	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
75	CD	75	75	75	N	O
mcg	NN	mcg	mcg	mcg	N	O
and	CC	and	and	and	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
during	IN	during	during	dure	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
month	NN	month	month	month	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	O
frequently	RB	frequently	frequently	frequent	N	O
occurring	VBG	occurring	occurring	occur	N	O
specific	JJ	specific	specific	specif	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
for	IN	for	for	for	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
75	CD	75	75	75	N	O
mcg	NN	mcg	mcg	mcg	N	O
(	(	(	(	(	N	O
frequency	NN	frequency	frequency	frequenc	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Additional	JJ	additional	additional	addit	N	O

adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
dosed	VBN	dosed	dosed	dose	N	O
with	IN	with	with	with	N	O
150	CD	150	150	150	N	O
,	,	,	,	,	N	O
300	CD	300	300	300	N	O
or	CC	or	or	or	N	O
600	CD	600	600	600	N	O
mcg	NN	mcg	mcg	mcg	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
were	VBD	were	were	were	N	O
as	IN	as	a	as	N	O
follows	VBZ	follows	follows	follow	N	O
:	:	:	:	:	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasm	NN	spasm	spasm	spasm	N	I-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
peripheral	NN	peripheral	peripheral	peripher	N	I-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorder	NN	disorder	disorder	disord	N	O
:	:	:	:	:	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	B-AdverseReaction
mellitus	VBP	mellitus	mellitus	mellitu	N	I-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

C	NNP	c	c	c	N	O
ough	NN	ough	ough	ough	N	O
experienced	VBD	experienced	experienced	experienc	N	O
p	NN	p	p	p	Y	O
ost	SYM	ost	ost	ost	N	O
-	:	-	-	-	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O

In	IN	in	in	in	N	O

the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
health	NN	health	health	health	N	O
care	NN	care	care	care	N	O
providers	NNS	providers	provider	provid	N	O
observed	VBD	observed	observed	observ	N	O
during	IN	during	during	dure	N	O
clinic	JJ	clinic	clinic	clinic	N	O
visits	NNS	visits	visit	visit	N	O
that	IN	that	that	that	N	O
an	DT	an	an	an	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
24%	CD	24%	24%	24%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
on	IN	on	on	on	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
20%	CD	20%	20%	20%	N	O
of	IN	of	of	of	N	O
visits	NNS	visits	visit	visit	N	O
following	VBG	following	following	follow	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
75	CD	75	75	75	N	O
mcg	NN	mcg	mcg	mcg	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
7%	CD	7%	7%	7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
usually	RB	usually	usually	usual	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
15	CD	15	15	15	N	O
seconds	NNS	seconds	second	second	N	O
following	VBG	following	following	follow	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
and	CC	and	and	and	N	O
lasted	VBD	lasted	lasted	last	N	O
for	IN	for	for	for	N	O
no	DT	no	no	no	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
15	CD	15	15	15	N	O
seconds	NNS	seconds	second	second	N	O
.	.	.	.	.	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
following	VBG	following	following	follow	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	B-Negation
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction
,	,	,	,	,	N	O
exacerbations	NNS	exacerbations	exacerbation	exacerb	N	I-AdverseReaction
,	,	,	,	,	N	O
deteriorations	NNS	deteriorations	deterioration	deterior	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
or	CC	or	or	or	N	O
loss	NN	loss	loss	loss	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
efficacy	NN	efficacy	efficacy	efficaci	N	I-AdverseReaction
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Asthma	NNP	asthma	asthma	asthma	Y	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
randomized	VBD	randomized	randomized	random	N	O
,	,	,	,	,	N	O
active	JJ	active	active	activ	N	O
controlled	VBD	controlled	controlled	control	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
safety	NN	safety	safety	safeti	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
805	CD	805	805	805	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
severe	VB	severe	severe	sever	N	O
persistent	JJ	persistent	persistent	persist	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
300	CD	300	300	300	N	O
mcg	NN	mcg	mcg	mcg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
268	CD	268	268	268	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
600	CD	600	600	600	N	O
mcg	NN	mcg	mcg	mcg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
268	CD	268	268	268	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
269	CD	269	269	269	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
with	IN	with	with	with	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
co	JJ	co	co	co	N	O
-	:	-	-	-	N	O
randomized	NN	randomized	randomized	random	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
2	CD	2	2	2	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
300	CD	300	300	300	N	O
mcg	NN	mcg	mcg	mcg	N	O
dose	NN	dose	dose	dose	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	B-Negation
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
600	CD	600	600	600	N	O
mcg	NN	mcg	mcg	mcg	N	O
dose	NN	dose	dose	dose	N	O
group	NN	group	group	group	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
active	JJ	active	active	activ	N	O
control	NN	control	control	control	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
asthma	VB	asthma	asthma	asthma	Y	B-AdverseReaction
exacerbation	NN	exacerbation	exacerbation	exacerb	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
2	CD	2	2	2	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
indacaterol	NN	indacaterol	indacaterol	indacaterol	N	O
300	CD	300	300	300	N	O
mcg	NN	mcg	mcg	mcg	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
indacaterol	NN	indacaterol	indacaterol	indacaterol	N	O
600	CD	600	600	600	N	O
mcg	NN	mcg	mcg	mcg	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
active	JJ	active	active	activ	N	O
control	NN	control	control	control	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
two	CD	two	two	two	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
ranging	VBG	ranging	ranging	rang	N	O
trial	NN	trial	trial	trial	N	O
was	VBD	was	wa	wa	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
511	CD	511	511	511	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
mild	JJ	mild	mild	mild	N	O
persistent	JJ	persistent	persistent	persist	N	O
asthma	NN	asthma	asthma	asthma	Y	O
taking	VBG	taking	taking	take	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
deaths	NNS	deaths	death	death	N	B-AdverseReaction
,	,	,	,	,	N	O
intubations	NNS	intubations	intubation	intub	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
asthma	VB	asthma	asthma	asthma	Y	B-AdverseReaction
exacerbation	NN	exacerbation	exacerbation	exacerb	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
worldwide	NN	worldwide	worldwide	worldwid	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
indacaterol	NN	indacaterol	indacaterol	indacaterol	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
ingredient	NN	ingredient	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
paradoxical	JJ	paradoxical	paradoxical	paradox	N	B-AdverseReaction
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	I-AdverseReaction
,	,	,	,	,	N	O
tachycardia	JJ	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
heart	NN	heart	heart	heart	N	B-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
increase	NN	increase	increase	increas	N	I-AdverseReaction
palpitations	NNS	palpitations	palpitation	palpit	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
rash	NN	rash	rash	rash	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ASTHMA	NNP	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
DEATH	NNP	death	death	death	Y	B-AdverseReaction
\n\n	NN	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ASTHMA	NNP	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
DEATH	NNP	death	death	death	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
L	NNP	l	l	l	N	B-DrugClass
ong	IN	ong	ong	ong	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
acting	VBG	acting	acting	act	N	I-DrugClass
beta	NN	beta	beta	beta	N	I-DrugClass
2	CD	2	2	2	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
s	NN	s	s	s	N	I-DrugClass
(	(	(	(	(	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
)	)	)	)	)	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
large	JJ	large	large	larg	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
US	NNP	us	u	us	N	O
study	NN	study	study	studi	N	O
that	WDT	that	that	that	N	O
compared	VBN	compared	compared	compar	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
long	JJ	long	long	long	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
acting	VBG	acting	acting	act	N	I-DrugClass
beta	NN	beta	beta	beta	N	I-DrugClass
2	CD	2	2	2	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
(	(	(	(	(	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
added	VBN	added	added	ad	N	O
to	TO	to	to	to	N	O
usual	JJ	usual	usual	usual	N	O
asthma	NN	asthma	asthma	asthma	Y	O
therapy	NN	therapy	therapy	therapi	N	O
showed	VBD	showed	showed	show	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
finding	NN	finding	finding	find	N	O
with	IN	with	with	with	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
is	VBZ	is	is	is	N	O
considered	VBN	considered	considered	consid	N	O
a	DT	a	a	a	N	O
class	NN	class	class	class	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
LABA	NNP	laba	laba	laba	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
indacaterol	NN	indacaterol	indacaterol	indacaterol	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
ingredient	NN	ingredient	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
RCAPTA	NNP	rcapta	rcapta	rcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
C	NNP	c	c	c	N	O
ontraindications	NNS	ontraindications	ontraindications	ontraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
W	NNP	w	w	w	N	O
arnings	NNS	arnings	arnings	arn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ASTHMA	NNP	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
DEATH	NNP	death	death	death	Y	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
\n\n\n\n	NN	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Long	NNP	long	long	long	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
acting	VBG	acting	acting	act	N	I-DrugClass
beta2	SYM	beta2	beta2	beta2	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
(	(	(	(	(	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
)	)	)	)	)	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
long	JJ	long	long	long	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
acting	VBG	acting	acting	act	N	I-DrugClass
beta2	SYM	beta2	beta2	beta2	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
(	(	(	(	(	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
)	)	)	)	)	N	O
showed	VBD	showed	showed	show	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
This	DT	this	this	thi	N	O
finding	NN	finding	finding	find	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
with	IN	with	with	with	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
is	VBZ	is	is	is	N	O
considered	VBN	considered	considered	consid	N	O
a	DT	a	a	a	N	O
class	NN	class	class	class	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
LABA	NNP	laba	laba	laba	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
indacaterol	NN	indacaterol	indacaterol	indacaterol	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
ingredient	NN	ingredient	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
initiate	VB	initiate	initiate	initi	N	O
in	IN	in	in	in	N	O
acutely	RB	acutely	acutely	acut	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
COPD	NNP	copd	copd	copd	Y	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
for	IN	for	for	for	N	O
relief	NN	relief	relief	relief	N	O
of	IN	of	of	of	N	O
acute	NN	acute	acute	acut	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

Concomitant	NNP	concomitant	concomitant	concomit	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonists	NNS	agonists	agonist	agonist	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
as	IN	as	a	as	N	O
needed	VBN	needed	needed	need	N	O
for	IN	for	for	for	N	O
acute	JJ	acute	acute	acut	N	O
relief	NN	relief	relief	relief	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
exceed	VB	exceed	exceed	exceed	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Excessive	JJ	excessive	excessive	excess	N	O
use	NN	use	use	use	N	O
or	CC	or	or	or	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
medications	NNS	medications	medication	medic	N	O
containing	VBG	containing	containing	contain	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
can	MD	can	can	can	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	B-Severity
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Immediate	NNP	immediate	immediate	immedi	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
immediately	RB	immediately	immediately	immedi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Life	NNP	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
paradoxical	JJ	paradoxical	paradoxical	paradox	N	B-AdverseReaction
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
immediately	RB	immediately	immediately	immedi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
or	CC	or	or	or	N	O
convulsive	JJ	convulsive	convulsive	convuls	N	O
disorders	NNS	disorders	disorder	disord	N	O
,	,	,	,	,	N	O
thyrotoxicosis	NN	thyrotoxicosis	thyrotoxicosis	thyrotoxicosi	Y	O
or	CC	or	or	or	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
to	TO	to	to	to	N	O
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
,	,	,	,	,	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Asthma	NN	asthma	asthma	asthma	Y	O

-	:	-	-	-	N	O
Related	VBN	related	related	relat	N	O
Death	NNP	death	death	death	Y	O
[	NNP	[	[	[	N	O
See	NNP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
]	NN	]	]	]	N	O

Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
large	JJ	large	large	larg	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
asthma	NN	asthma	asthma	asthma	Y	O
patients	NNS	patients	patient	patient	N	O
showed	VBD	showed	showed	show	N	O
that	IN	that	that	that	N	O
long	JJ	long	long	long	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
acting	VBG	acting	acting	act	N	I-DrugClass
beta	NN	beta	beta	beta	N	I-DrugClass
2	CD	2	2	2	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
is	VBZ	is	is	is	N	O
increased	VBN	increased	increased	increas	N	O
by	IN	by	by	by	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta	NN	beta	beta	beta	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
adrenergic	NN	adrenergic	adrenergic	adrenerg	N	O
agonists	NNS	agonists	agonist	agonist	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
28	CD	28	28	28	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
US	NNP	us	u	us	N	O
study	NN	study	study	studi	N	O
comparing	VBG	comparing	comparing	compar	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
long	JJ	long	long	long	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
acting	VBG	acting	acting	act	N	I-DrugClass
beta	NN	beta	beta	beta	N	I-DrugClass
2	CD	2	2	2	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
(	(	(	(	(	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
each	DT	each	each	each	N	O
added	VBD	added	added	ad	N	O
to	TO	to	to	to	N	O
usual	JJ	usual	usual	usual	N	O
asthma	NN	asthma	asthma	asthma	Y	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
showed	VBD	showed	showed	show	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
13	CD	13	13	13	N	O
,	,	,	,	,	N	O
176	CD	176	176	176	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

3	CD	3	3	3	N	O
13	CD	13	13	13	N	O
,	,	,	,	,	N	O
179	CD	179	179	179	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
;	:	;	;	;	N	O
RR	NNP	rr	rr	rr	N	O
4.37	CD	4.37	4.37	4.37	N	O
,	,	,	,	,	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
1.25	CD	1.25	1.25	1.25	N	O
,	,	,	,	,	N	O
15.34	CD	15.34	15.34	15.34	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
considered	VBN	considered	considered	consid	N	O
a	DT	a	a	a	N	O
class	NN	class	class	class	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta	NN	beta	beta	beta	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
adrenergic	NN	adrenergic	adrenergic	adrenerg	N	O
agonists	NNS	agonists	agonist	agonist	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
study	NN	study	study	studi	N	O
adequate	VB	adequate	adequate	adequ	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
asthma	NN	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	O
is	VBZ	is	is	is	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
conducted	VBN	conducted	conducted	conduct	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
asthma	SYM	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
death	NN	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
sizes	NN	sizes	size	size	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
adequate	JJ	adequate	adequate	adequ	N	O
to	TO	to	to	to	N	O
precisely	RB	precisely	precisely	precis	N	O
quantify	VB	quantify	quantify	quantifi	N	O
the	DT	the	the	the	N	O
differences	NNS	differences	difference	differ	N	O
in	IN	in	in	in	N	O
serious	JJ	serious	serious	seriou	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
rates	NNS	rates	rate	rate	N	O
between	IN	between	between	between	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Deterioration	NN	deterioration	deterioration	deterior	N	O
of	IN	of	of	of	N	O
Disease	NNP	disease	disease	diseas	N	O
and	CC	and	and	and	N	O
Acute	NNP	acute	acute	acut	N	O
Episodes	NNP	episodes	episode	episod	N	O

ARCAPTA	NN	arcapta	arcapta	arcapta	N	O

NEOHALER	NNP	neohaler	neohaler	neohal	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
acutely	RB	acutely	acutely	acut	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
COPD	NNP	copd	copd	copd	Y	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	JJ	threatening	threatening	threaten	N	O
condition	NN	condition	condition	condit	N	O
.	.	.	.	.	N	O

ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
acutely	RB	acutely	acutely	acut	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
COPD	NNP	copd	copd	copd	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
setting	NN	setting	setting	set	N	O
is	VBZ	is	is	is	N	O
inappropriate	JJ	inappropriate	inappropriate	inappropri	N	O
.	.	.	.	.	N	O

ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
relief	NN	relief	relief	relief	N	O
of	IN	of	of	of	N	O
acute	NN	acute	acute	acut	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O

as	IN	as	a	as	N	O
rescue	NN	rescue	rescue	rescu	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	O
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	O
.	.	.	.	.	N	O

ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
relief	NN	relief	relief	relief	N	O
of	IN	of	of	of	N	O
acute	NN	acute	acute	acut	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
extra	JJ	extra	extra	extra	N	O
doses	NNS	doses	dos	dose	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
that	DT	that	that	that	N	O
purpose	NN	purpose	purpose	purpos	N	O
.	.	.	.	.	N	O

Acute	NNP	acute	acute	acut	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
inhaled	VBN	inhaled	inhaled	inhal	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
beginning	VBG	beginning	beginning	begin	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
taking	VBG	taking	taking	take	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonists	NNS	agonists	agonist	agonist	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
regular	JJ	regular	regular	regular	N	O
basis	NN	basis	basis	basi	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
four	CD	four	four	four	N	O
times	NNS	times	time	time	N	O
a	DT	a	a	a	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
the	DT	the	the	the	N	O
regular	JJ	regular	regular	regular	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
drugs	NNS	drugs	drug	drug	N	O
and	CC	and	and	and	N	O
use	VB	use	use	use	N	O
them	PRP	them	them	them	N	O
only	RB	only	only	onli	N	O
for	IN	for	for	for	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
relief	NN	relief	relief	relief	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
prescribe	VB	prescribe	prescribe	prescrib	N	O
an	DT	an	an	an	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
and	CC	and	and	and	N	O
instruct	VB	instruct	instruct	instruct	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
how	WRB	how	how	how	N	O
it	PRP	it	it	it	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
.	.	.	.	.	N	O

Increasing	VBG	increasing	increasing	increas	N	O
inhaled	VBN	inhaled	inhaled	inhal	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
use	NN	use	use	use	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
signal	NN	signal	signal	signal	N	O
of	IN	of	of	of	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
disease	NN	disease	disease	diseas	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
prompt	JJ	prompt	prompt	prompt	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
is	VBZ	is	is	is	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

COPD	NNP	copd	copd	copd	Y	O
may	MD	may	may	may	N	O
deteriorate	VB	deteriorate	deteriorate	deterior	N	O
acutely	RB	acutely	acutely	acut	N	O
over	IN	over	over	over	N	O
a	DT	a	a	a	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
hours	NNS	hours	hour	hour	N	O
or	CC	or	or	or	N	O
chronically	RB	chronically	chronically	chronic	N	O
over	IN	over	over	over	N	O
several	JJ	several	several	sever	N	O
days	NNS	days	day	day	N	O
or	CC	or	or	or	N	O
longer	JJR	longer	longer	longer	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
no	RB	no	no	no	N	O
longer	RB	longer	longer	longer	N	O
controls	VBZ	controls	control	control	N	O
the	DT	the	the	the	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
bronchoconstriction	NN	bronchoconstriction	bronchoconstriction	bronchoconstrict	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
becomes	VBZ	becomes	becomes	becom	N	O
less	RBR	less	le	less	N	O
effective	JJ	effective	effective	effect	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
patient	JJ	patient	patient	patient	N	O
needs	VBZ	needs	need	need	N	O
more	JJR	more	more	more	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
of	IN	of	of	of	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
than	IN	than	than	than	N	O
usual	JJ	usual	usual	usual	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
markers	NNS	markers	marker	marker	N	O
of	IN	of	of	of	N	O
deterioration	NN	deterioration	deterioration	deterior	N	O
of	IN	of	of	of	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
setting	NN	setting	setting	set	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
re	NN	re	re	re	N	O
-	:	-	-	-	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
COPD	NNP	copd	copd	copd	Y	O
treatment	NN	treatment	treatment	treatment	N	O
regimen	NNS	regimen	regimen	regimen	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
undertaken	VBN	undertaken	undertaken	undertaken	N	O
at	IN	at	at	at	N	O
once	RB	once	once	onc	N	O
.	.	.	.	.	N	O

Increasing	VBG	increasing	increasing	increas	N	O
the	DT	the	the	the	N	O
daily	JJ	daily	daily	daili	N	O
dosage	NN	dosage	dosage	dosag	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
beyond	IN	beyond	beyond	beyond	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
situation	NN	situation	situation	situat	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Excessive	JJ	excessive	excessive	excess	N	O
Use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Other	JJ	other	other	other	N	O
Long	NNP	long	long	long	N	O
-	:	-	-	-	N	O
Acting	VBG	acting	acting	act	N	O
Beta2	NNP	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
Agonists	NNS	agonists	agonist	agonist	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
adrenergic	NN	adrenergic	adrenergic	adrenerg	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
more	RBR	more	more	more	N	O
often	RB	often	often	often	N	O
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
doses	NNS	doses	dos	dose	N	O
than	IN	than	than	than	N	O
recommended	VBN	recommended	recommended	recommend	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
medications	NNS	medications	medication	medic	N	O
containing	VBG	containing	containing	contain	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonists	NNS	agonists	agonist	agonist	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
overdose	NN	overdose	overdose	overdos	Y	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
.	.	.	.	.	N	O

Clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
effects	NNS	effects	effect	effect	N	O
and	CC	and	and	and	N	O
fatalities	NNS	fatalities	fatality	fatal	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
excessive	JJ	excessive	excessive	excess	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Immediate	NNP	immediate	immediate	immedi	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Immediate	NNP	immediate	immediate	immedi	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
signs	NNS	signs	sign	sign	N	O
suggesting	VBG	suggesting	suggesting	suggest	N	O
allergic	JJ	allergic	allergic	allerg	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
in	IN	in	in	in	N	O
particular	NN	particular	particular	particular	N	O
,	,	,	,	,	N	O
difficulties	NNS	difficulties	difficulty	difficulti	N	O
in	IN	in	in	in	N	O
breathing	NN	breathing	breathing	breath	N	O
or	CC	or	or	or	N	O
swallowing	NN	swallowing	swallowing	swallow	N	O
,	,	,	,	,	N	O
swelling	VBG	swelling	swelling	swell	Y	O
of	IN	of	of	of	N	O
tongue	NN	tongue	tongue	tongu	N	O
,	,	,	,	,	N	O
lips	NNS	lips	lip	lip	N	O
and	CC	and	and	and	N	O
face	NN	face	face	face	N	O
,	,	,	,	,	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	O
,	,	,	,	,	N	O
skin	JJ	skin	skin	skin	N	O
rash	NN	rash	rash	rash	Y	O
)	)	)	)	)	N	O
occur	NN	occur	occur	occur	N	O
,	,	,	,	,	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
immediately	RB	immediately	immediately	immedi	N	O
and	CC	and	and	and	N	O
alternative	JJ	alternative	alternative	altern	N	O
therapy	NN	therapy	therapy	therapi	N	O
instituted	VBN	instituted	instituted	institut	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Paradoxical	JJ	paradoxical	paradoxical	paradox	N	O
Bronchospasm	NNP	bronchospasm	bronchospasm	bronchospasm	Y	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonists	NNS	agonists	agonist	agonist	N	O
,	,	,	,	,	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
may	MD	may	may	may	N	B-Factor
produce	VB	produce	produce	produc	N	O
paradoxical	JJ	paradoxical	paradoxical	paradox	N	B-AdverseReaction
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	I-AdverseReaction
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
paradoxical	JJ	paradoxical	paradoxical	paradox	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	O
occurs	NNS	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
immediately	RB	immediately	immediately	immedi	N	O
and	CC	and	and	and	N	O
alternative	JJ	alternative	alternative	altern	N	O
therapy	NN	therapy	therapy	therapi	N	O
instituted	VBN	instituted	instituted	institut	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
Effects	NNS	effects	effect	effect	N	O

ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
,	,	,	,	,	N	O
like	IN	like	like	like	N	O
other	JJ	other	other	other	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonists	NNS	agonists	agonist	agonist	N	O
,	,	,	,	,	N	O
can	MD	can	can	can	N	B-Factor
produce	VB	produce	produce	produc	N	O
a	DT	a	a	a	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	B-Severity
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
effect	NN	effect	effect	effect	N	I-AdverseReaction
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
as	IN	as	a	as	N	O
measured	VBN	measured	measured	measur	N	O
by	IN	by	by	by	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
pulse	JJ	pulse	pulse	puls	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
,	,	,	,	,	N	O
systolic	NN	systolic	systolic	systol	N	I-AdverseReaction
or	CC	or	or	or	N	O
diastolic	JJ	diastolic	diastolic	diastol	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
effects	NNS	effects	effect	effect	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
may	MD	may	may	may	N	O
need	VB	need	need	need	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
beta	SYM	beta	beta	beta	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
ECG	NNP	ecg	ecg	ecg	Y	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
flattening	NN	flattening	flattening	flatten	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
T	NNP	t	t	t	N	I-AdverseReaction
wave	NN	wave	wave	wave	N	I-AdverseReaction
,	,	,	,	,	N	O
prolongation	NN	prolongation	prolongation	prolong	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
QTc	NNP	qtc	qtc	qtc	Y	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ST	NNP	st	st	st	N	B-AdverseReaction
segment	NN	segment	segment	segment	N	I-AdverseReaction
depression	NN	depression	depression	depress	Y	I-AdverseReaction
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
findings	NNS	findings	finding	find	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
,	,	,	,	,	N	O
like	IN	like	like	like	N	O
other	JJ	other	other	other	N	O
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	O
amines	NNS	amines	amine	amin	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
coronary	JJ	coronary	coronary	coronari	N	O
insufficiency	NN	insufficiency	insufficiency	insuffici	N	O
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Coexisting	NNP	coexisting	coexisting	coexist	N	O
Conditions	NNS	conditions	condition	condit	N	O

ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
,	,	,	,	,	N	O
like	IN	like	like	like	N	O
other	JJ	other	other	other	N	O
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	O
amines	NNS	amines	amine	amin	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
convulsive	JJ	convulsive	convulsive	convuls	N	O
disorders	NNS	disorders	disorder	disord	N	O
or	CC	or	or	or	N	O
thyrotoxicosis	NN	thyrotoxicosis	thyrotoxicosis	thyrotoxicosi	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
unusually	RB	unusually	unusually	unusu	N	O
responsive	JJ	responsive	responsive	respons	N	O
to	TO	to	to	to	N	O
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	O
amines	NNS	amines	amine	amin	N	O
.	.	.	.	.	N	O

Doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
related	JJ	related	related	relat	N	O
beta2	NN	beta2	beta2	beta2	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
albuterol	NN	albuterol	albuterol	albuterol	N	O
,	,	,	,	,	N	O
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
intravenously	RB	intravenously	intravenously	intraven	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
aggravate	VB	aggravate	aggravate	aggrav	N	B-AdverseReaction
pre	JJ	pre	pre	pre	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
existing	VBG	existing	existing	exist	N	I-AdverseReaction
diabetes	NNS	diabetes	diabetes	diabet	Y	I-AdverseReaction
mellitus	NNS	mellitus	mellitus	mellitu	N	I-AdverseReaction
and	CC	and	and	and	N	O
ketoacidosis	NN	ketoacidosis	ketoacidosis	ketoacidosi	Y	I-AdverseReaction
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	O
and	CC	and	and	and	N	O
Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	O

Beta2	NNP	beta2	beta2	beta2	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
medications	NNS	medications	medication	medic	N	O
may	MD	may	may	may	N	O
produce	VB	produce	produce	produc	N	O
significant	JJ	significant	significant	signific	N	B-Severity
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
possibly	RB	possibly	possibly	possibl	N	O
through	IN	through	through	through	N	O
intracellular	JJ	intracellular	intracellular	intracellular	N	O
shunting	NN	shunting	shunting	shunt	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
has	VBZ	has	ha	ha	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
adverse	JJ	adverse	adverse	advers	N	B-AdverseReaction
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	I-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
potassium	NN	potassium	potassium	potassium	Y	I-AdverseReaction
is	VBZ	is	is	is	N	O
usually	RB	usually	usually	usual	N	O
transient	JJ	transient	transient	transient	N	O
,	,	,	,	,	N	O
not	RB	not	not	not	N	O
requiring	VBG	requiring	requiring	requir	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
.	.	.	.	.	N	O

Inhalation	NN	inhalation	inhalation	inhal	N	O
of	IN	of	of	of	N	O
high	JJ	high	high	high	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
beta2	NN	beta2	beta2	beta2	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
may	MD	may	may	may	N	O
produce	VB	produce	produce	produc	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
plasma	NN	plasma	plasma	plasma	N	I-AdverseReaction
glucose	NN	glucose	glucose	glucos	Y	I-AdverseReaction
.	.	.	.	.	N	O

Clinically	RB	clinically	clinically	clinic	N	O
notable	JJ	notable	notable	notabl	N	O
decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
potassium	NN	potassium	potassium	potassium	Y	I-AdverseReaction
or	CC	or	or	or	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
glucose	NN	glucose	glucose	glucos	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
infrequent	JJ	infrequent	infrequent	infrequ	N	O
during	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
controls	NNS	controls	control	control	N	O
.	.	.	.	.	N	O

ARCAPTA	NNP	arcapta	arcapta	arcapta	N	O
NEOHALER	NNP	neohaler	neohaler	neohal	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
investigated	VBN	investigated	investigated	investig	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	VBP	mellitus	mellitus	mellitu	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
well	RB	well	well	well	N	O
controlled	VBN	controlled	controlled	control	N	O
.	.	.	.	.	N	O

